Business Context and Reporting Period
Company: Stereotaxis, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 7, 2006
Reporting Period: Single event date (February 7, 2006)
This filing serves as a Regulation FD disclosure regarding a regulatory approval received by a partner company, Biosense Webster, Inc., involving technology designed by Stereotaxis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
Regulatory Approval: On February 7, 2006, Biosense Webster, Inc. announced FDA approval for the NAVISTAR RMT Diagnostic/Ablation Steerable Tip Catheter. This device is designed for use with:
- The Niobe Magnetic Navigation System (designed by Stereotaxis, Inc.)
- The CARTO RMT system (from Biosense Webster, Inc.)
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release from Biosense Webster, Inc. (Exhibit 99.1) but does not include specific management commentary, forward-looking guidance, or risk factors within the body of this 8-K text.
Legal Disclaimer: The information furnished in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings. It is not an admission as to the materiality of the information.
Investor Verification Checklist
- Verify the full text of the Biosense Webster, Inc. press release (Exhibit 99.1) for specific commercial implications.
- Confirm the commercial launch timeline for the NAVISTAR RMT catheter with the Niobe system.
- Assess the potential revenue impact of this FDA approval on Stereotaxis's licensing or royalty agreements with Biosense Webster.
- Review subsequent filings for any financial updates related to this regulatory milestone.